Published in J Asthma Allergy on August 13, 2010
An estimate of asthma prevalence in Africa: a systematic analysis. Croat Med J (2013) 0.99
Update on optimal use of omalizumab in management of asthma. J Asthma Allergy (2011) 0.83
Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. NPJ Prim Care Respir Med (2014) 0.83
LABA monotherapy in asthma: an avoidable problem. Br J Gen Pract (2013) 0.79
Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children. Am J Manag Care (2015) 0.75
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (1996) 10.84
The global burden of asthma. Chest (2006) 5.74
The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics (1993) 2.26
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy (2007) 2.22
Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest (2001) 2.09
Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics (2002) 1.51
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatr Allergy Immunol (2006) 1.45
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol (2005) 1.45
Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin (2006) 1.06
A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma. Respir Med (2001) 0.91
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol (2003) 0.90
National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med (1996) 0.89
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess (2008) 0.89
Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group. Br J Clin Pract (1997) 0.87
Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treat Respir Med (2005) 0.85
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin (2006) 0.85
Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics (2006) 0.84
Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. Eur Respir J (2004) 0.84
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics (2004) 0.83
Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract (2003) 0.83
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics (2001) 0.83
Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics (1998) 0.81
Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain. Int J Clin Pract (2005) 0.81
An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respir Med (2004) 0.81
Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respir Med (2005) 0.81
Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics (1993) 0.81
Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Ann Allergy Asthma Immunol (2004) 0.80
Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Ann Allergy Asthma Immunol (2001) 0.79
Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. Pharmacoeconomics (1999) 0.79
Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respir Med (2002) 0.79
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics (2005) 0.79
A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics (1996) 0.78
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics (2002) 0.78
Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study. Respir Med (2001) 0.78
Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics? Respir Med (1998) 0.77
Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Investig (1998) 0.77
Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. Respir Med (2003) 0.77
Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One (2009) 4.92
Overdiagnosis of asthma in obese and nonobese adults. CMAJ (2008) 3.23
Economic burden of asthma: a systematic review. BMC Pulm Med (2009) 3.10
Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults. Can Respir J (2010) 2.42
Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis. Chest (2006) 2.37
Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med (2010) 2.31
Empyema: an increasing concern in Canada. Can Respir J (2008) 2.26
Bronchial thermoplasty for asthma. Am J Respir Crit Care Med (2006) 2.15
The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care (2010) 1.95
Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics (2009) 1.92
Research gaps in protecting healthcare workers from SARS and other respiratory pathogens: an interdisciplinary, multi-stakeholder, evidence-based approach. J Occup Environ Med (2005) 1.70
Antibiotic use in children is associated with increased risk of asthma. Pediatrics (2009) 1.68
Nurse staffing levels and hospital mortality in critical care settings: literature review and meta-analysis. J Adv Nurs (2006) 1.60
The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med (2010) 1.56
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics (2009) 1.55
Determinants of hospital length of stay among patients with pneumonia admitted to a large Canadian hospital from 1991 to 2001. Can Respir J (2005) 1.52
Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study. J Allergy Clin Immunol (2013) 1.48
Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis. Chest (2009) 1.47
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia (2014) 1.46
The "Lost NNT" can be used to represent uncertainty surrounding number needed to treat. J Clin Epidemiol (2012) 1.38
Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes (2004) 1.35
Health state utilities in latent and active tuberculosis. Value Health (2008) 1.34
In-depth analysis of patient-clinician cell phone communication during the WelTel Kenya1 antiretroviral adherence trial. PLoS One (2012) 1.30
Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. Chest (2008) 1.29
Time on wait lists for coronary bypass surgery in British Columbia, Canada, 1991-2000. BMC Health Serv Res (2005) 1.27
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum (2007) 1.19
A systematic review of asthma and health literacy: a cultural-ethnic perspective in Canada. MedGenMed (2007) 1.18
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. Value Health (2013) 1.05
A comparison of obese and nonobese people with asthma: exploring an asthma-obesity interaction. Chest (2010) 1.04
Direct health care costs associated with asthma in British Columbia. Can Respir J (2010) 1.03
Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest (2013) 1.01
Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep Breath (2012) 0.97
Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. J Clin Epidemiol (2008) 0.97
Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Can Respir J (2010) 0.96
Variations in the management of acute exacerbations of chronic obstructive pulmonary disease. Can Respir J (2013) 0.96
Current recommendations for the treatment of mild asthma. J Asthma Allergy (2010) 0.95
Socioeconomic status and hospital utilization among younger adult pneumonia admissions at a Canadian hospital. BMC Health Serv Res (2006) 0.93
Reconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. Chest (2004) 0.93
An ounce of prevention is worth a pound of cure: a cost-effectiveness analysis of incidentally detected aneurysms in functional MRI research. Value Health (2010) 0.90
A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc (2015) 0.90
An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health Qual Life Outcomes (2004) 0.88
Health literacy, language, and ethnicity-related factors in newcomer asthma patients to Canada: a qualitative study. J Immigr Minor Health (2011) 0.85
Peripheral blood gene expression changes during allergen inhalation challenge in atopic asthmatic individuals. J Asthma (2012) 0.85
The demise of portable monitoring to diagnose OSA? Not so fast! Sleep (2011) 0.83
Ontario's plunging price-caps on generics: deeper dives may drown some drugs. Open Med (2011) 0.83
Barriers for integrating personalized medicine into clinical practice: a qualitative analysis. Am J Med Genet A (2013) 0.82
Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs (2003) 0.81
Impact of allowing pharmacists to independently renew prescriptions: A population-based study. J Am Pharm Assoc (2003) (2015) 0.80
Costs and health outcomes associated with primary vs secondary care after an asthma-related hospitalization: a population-based study. Chest (2013) 0.80
Complementary and alternative asthma treatments and their association with asthma control: a population-based study. BMJ Open (2013) 0.80
An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experiment. J Asthma (2008) 0.79
Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge. Proteomics Clin Appl (2012) 0.79
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev (2010) 0.79
What counts as cultural competency in telehealth interventions? A call for new directions. J Telemed Telecare (2012) 0.78
Continuous positive airway pressure therapy for obstructive sleep apnea syndrome: do the dollars make sense? Sleep (2005) 0.78
The impact of housestaff fatigue on occupational and patient safety. Lung (2007) 0.78
The impact of asthma guidelines. Lancet (2010) 0.78
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev (2010) 0.77
Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum (2008) 0.77
Maternal stress: a cause of childhood asthma? Am J Respir Crit Care Med (2012) 0.76
A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health (2013) 0.75
A new era of personalized medicine for cystic fibrosis - at last! Can Respir J (2015) 0.75
The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth (2016) 0.75
"Employment and arthritis: making it work" a randomized controlled trial evaluating an online program to help people with inflammatory arthritis maintain employment (study protocol). BMC Med Inform Decis Mak (2014) 0.75
Optic disc swelling and vision loss in a patient with cystic fibrosis and diabetes. Case Rep Endocrinol (2013) 0.75
Post-hospital syndrome in adults with asthma: a case-crossover study. Allergy Asthma Clin Immunol (2013) 0.75
Evaluation of booking systems for elective surgery using simulation experiments. Healthc Policy (2008) 0.75
Response. Chest (2013) 0.75
The cost of sleep disorders: no snoring matter. Sleep (2006) 0.75
Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. Trials (2014) 0.75
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev (2016) 0.75
Improving rheumatoid arthritis outcomes: how do we get there? Am J Health Syst Pharm (2006) 0.75
Asthma in adults. BMJ Clin Evid (2007) 0.75
Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. J Rheumatol (2007) 0.75
Asthma. Clin Evid (2004) 0.75
The challenge of making cost-effective asthma therapy available. Int J Tuberc Lung Dis (2009) 0.75
Asthma: improved understanding and insights into the challenges of achieving asthma control. Thorax (2010) 0.75
Two-level resampling as a novel method for the calculation of the expected value of sample information in economic trials. Health Econ (2012) 0.75
Technical note: acceptability curves could be misleading when correlated strategies are compared. Med Decis Making (2008) 0.75
Asthma. Clin Evid (2005) 0.75
An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation. Pharmacoeconomics (2004) 0.75